Recent advance of fluorescent probes for detection of drug-induced liver injury markers

被引:21
|
作者
Sun, Dongqin [1 ]
Chen, Zhenzhen [1 ]
Hu, Jiali [1 ]
Zeng, Huajin [1 ]
Qu, Lingbo [2 ]
Yang, Ran [2 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
[2] Zhengzhou Univ, Coll Chem, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
Fluorescent probe; Drug-induced liver injury (DILI); Roussel uclaf causality assessment method (RUCAM); Clinical markers; Imaging; GLUTATHIONE-S-TRANSFERASE; IMAGING ENDOGENOUS PEROXYNITRITE; HIGHLY SELECTIVE DETECTION; ALANINE AMINOTRANSFERASE; INDUCED HEPATOTOXICITY; ENDOPLASMIC-RETICULUM; BIOLUMINESCENT PROBE; CAUSALITY ASSESSMENT; HYPOCHLOROUS ACID; ADVERSE REACTIONS;
D O I
10.1016/j.cclet.2021.12.043
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Drug-induced liver injury (DILI) is a common and serious adverse drug reaction. At present, DILI is perfectly diagnozed in clinical settings using Roussel Uclaf causality assessment method (RUCAM) in its original version published 1993 and its updated version published 2016, well established worldwide as a diagnostic algorithm with a high sensitivity and specificity. Nevertheless, the search for additional detection methods supporting RUCAM continues. In recent years, with the development of optical imaging technology, fluorescent probes have gradually shown great advantages in the detection and diagnosis of DILI markers such as high sensitivity, anti-interference, real-time monitoring and non-invasive measurement. In this review, the recent advances of fluorescent probes for evaluation of DILI in experimental studies were summarized according to various markers of DILI. We believe that learning about the design and practical application of these probes will contribute to the further development of detection sensors for DILI markers. (C) 2022 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
引用
收藏
页码:4478 / 4494
页数:17
相关论文
共 50 条
  • [21] Drug-induced liver injury
    Denk, H
    PATHOLOGY OF THE KIDNEYS AND URINARY PASSAGES - MOLECULAR VASCULAR PATHOLOGY AND ANGIOGENESIS, 2002, 86 : 120 - 125
  • [22] Drug-induced liver injury
    Aithal, G.
    DRUG SAFETY, 2017, 40 (10) : 1040 - 1040
  • [23] Drug-induced liver injury
    Kumachev, Alexander
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (09) : E310 - E310
  • [24] Drug-induced liver injury
    Andrade, Raul J.
    Chalasani, Naga
    Bjornsson, Einar S.
    Suzuki, Ayako
    Kullak-Ublick, Gerd A.
    Watkins, Paul B.
    Devarbhavi, Harshad
    Merz, Michael
    Isabel Lucena, M.
    Kaplowitz, Neil
    Aithal, Guruprasad P.
    NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [25] Drug-induced liver injury
    Grant, Lafaine M.
    Rockey, Don C.
    CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (03) : 198 - 202
  • [26] Drug-Induced Liver Injury
    Hamilton, Leslie A.
    Collins-Yoder, Angela
    Collins, Rachel E.
    AACN ADVANCED CRITICAL CARE, 2016, 27 (04) : 430 - 440
  • [28] Drug-induced liver injury
    Raul J. Andrade
    Naga Chalasani
    Einar S. Björnsson
    Ayako Suzuki
    Gerd A. Kullak-Ublick
    Paul B. Watkins
    Harshad Devarbhavi
    Michael Merz
    M. Isabel Lucena
    Neil Kaplowitz
    Guruprasad P. Aithal
    Nature Reviews Disease Primers, 5
  • [29] Drug-induced liver injury
    Abboud, Gebran
    Kaplowitz, Neil
    DRUG SAFETY, 2007, 30 (04) : 277 - 294
  • [30] Drug-Induced Liver Injury
    Gebran Abboud
    Neil Kaplowitz
    Drug Safety, 2007, 30 : 277 - 294